5:59 PM
 | 
Jan 14, 2013
 |  BC Extra  |  Company News

GSK submits albiglutide BLA

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) submitted a BLA to FDA for albiglutide to treat Type II...

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >